[go: up one dir, main page]

WO2007061001A1 - Complexe de support de gel et d'hydroxyapatite et procédé de production de celui-ci - Google Patents

Complexe de support de gel et d'hydroxyapatite et procédé de production de celui-ci Download PDF

Info

Publication number
WO2007061001A1
WO2007061001A1 PCT/JP2006/323343 JP2006323343W WO2007061001A1 WO 2007061001 A1 WO2007061001 A1 WO 2007061001A1 JP 2006323343 W JP2006323343 W JP 2006323343W WO 2007061001 A1 WO2007061001 A1 WO 2007061001A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxyapatite
gel
solution
gel carrier
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/323343
Other languages
English (en)
Japanese (ja)
Inventor
Mitsuru Akashi
Junji Watanabe
Takafumi Funaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOMEDICAL TECHNOLOGY HYBRID Ltd
Osaka Industrial Promotion Organization
University of Osaka NUC
Original Assignee
BIOMEDICAL TECHNOLOGY HYBRID Ltd
Osaka University NUC
Osaka Industrial Promotion Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOMEDICAL TECHNOLOGY HYBRID Ltd, Osaka University NUC, Osaka Industrial Promotion Organization filed Critical BIOMEDICAL TECHNOLOGY HYBRID Ltd
Priority to JP2007546472A priority Critical patent/JPWO2007061001A1/ja
Publication of WO2007061001A1 publication Critical patent/WO2007061001A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/831—Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
    • A61K6/838—Phosphorus compounds, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
    • A61K6/898—Polysaccharides

Definitions

  • the present invention relates to a composite of a gel carrier and hydroxyapatite and a method for producing the same.
  • nodoxyapatite is very similar to the components of bones and teeth, a complex in which hydroxyapatite is held on a base material such as an organic polymer material is used as an artificial bone or a human tooth root. Attempts have been made to use it as a forming material.
  • Patent Document 1 International Publication W099Z58447 Pamphlet
  • Patent Document 2 JP 2000-327313 A
  • Patent Document 3 Japanese Patent Laid-Open No. 2000-327314
  • Patent Document 4 Japanese Unexamined Patent Application Publication No. 2004-026653
  • Patent Document 5 Japanese Unexamined Patent Application Publication No. 2004-081739
  • the present invention provides a method for producing a composite that is excellent in the formation efficiency of hydroxyapatite and enables the formation of hydroxyapatite inside the substrate, and the composite produced thereby. For the purpose of provision.
  • the present invention provides a method for producing a composite of a gel carrier and hydroxyapatite, wherein the gel carrier is disposed between the anode and the cathode, and the electrophoretic solution on the anode side is obtained.
  • a solution containing calcium ions and a solution containing phosphate ions as an electrophoretic solution on the cathode side, and carrying out electrophoresis by energization to form hydroxyapatite in the gel carrier.
  • a solution containing calcium ions is used as the electrophoretic solution on the anode side, and a solution containing phosphate ions is used as the electrophoretic solution on the cathode side.
  • Uniform hydroxyapatite can be formed, and the formation speed can be improved. For this reason, it becomes possible to supply a complex in which hydroxyapatite is held on a gel carrier as a material for forming an artificial bone or an artificial tooth root more easily.
  • FIG. 1 is a conceptual diagram of electrophoresis in an embodiment of the present invention
  • FIG. 1 is a diagram showing an example of a reaction for forming hydroxyapatite.
  • FIG. 2 is a photograph showing an electrophoresis apparatus in one example of the present invention.
  • FIG. 3 is a photograph of the appearance of an agarose gel in the Example of the present invention.
  • FIG. 4 is an SEM photograph of the agarose gel in the example of the present invention, in which (a) is a non-turbid region (X 3000) on the anode side of the agarose gel, and (b) is a cathode of the agarose gel. Side cloudiness regions (X1500) and (c) are SEM photographs in which the magnification of the cloudiness region (X15000) is changed.
  • FIG. 5 is a SEM photograph of the agarose gel in the Example of the present invention, (A) is a SEM photograph of the central part of the cloudy area, and (B) is a SEM photograph of the surface part of the cloudy area. It is.
  • FIG. 6 is a graph showing the results of XRD analysis of the nodoxyapatite formed in the Example of the present invention.
  • FIG. 7A is a schematic view showing an example of an electrophoresis apparatus used in the production method of the present invention.
  • FIG. 7B is a schematic diagram showing another example of the electrophoresis apparatus used in the production method of the present invention.
  • the electrophoretic solution on the anode side only needs to contain calcium ions.
  • a solution containing a calcium compound (calcium salt) such as calcium chloride, calcium acetate, or calcium nitrate is preferable.
  • a solvent of the solution for example, an aqueous solvent such as water or a buffer solution is preferable, and a buffer solution capable of adjusting pH is particularly preferable.
  • a Tris buffer such as Tris-HCl buffer can be used.
  • Each of the calcium compounds and solvents can be one type! /, Or two or more types can be used together!
  • the concentration of calcium ions in the anodic electrophoretic solution is not particularly limited !, but is, for example, 10 to 200 mmol ZL, preferably 10 to 160 mmol ZL, and more preferably 10 to 40 mmol ZL.
  • the density of hydroxyapatite formed inside the gel carrier can be adjusted by, for example, the calcium ion concentration and the phosphate ion concentration of the cathode side electrophoresis solution described later.
  • the concentration of phosphate ion that preferably contains substantially no phosphate ion is, for example, lOmmolZL or less. Preferably, it is below the measurement limit (for example, OmmolZL).
  • the pH of the anodic electrophoretic solution is, for example, 4.6 to 9.2, preferably 5.8 to 8, and more preferably 6.6 to 7.4. It can be adjusted appropriately by using a buffer solution such as
  • the electrophoretic solution on the cathode side contains phosphate ions, and for example, sodium hydrogen phosphate, sodium dihydrogen phosphate, ammonium dihydrogen phosphate, ammonium dihydrogen phosphate A solution containing a phosphate compound such as hum is preferred.
  • a phosphate compound such as hum
  • an aqueous solvent such as water or a buffer solution is preferable.
  • the buffer for example, Tris buffer such as Tris-HCl buffer, phosphate buffer, etc. can be used, and the concentration thereof is, for example, 10 to 200 mmo 1 ZL, preferably 10 to 160 mmol ZL, and more. Preferably 10-40mmolZL It is. Either one type of phosphoric acid compound or solvent may be used, or two or more types may be used in combination.
  • the concentration of phosphate ions in the cathodic electrophoresis solution is not particularly limited !, but is, for example, 10 to 200 mmol ZL, preferably 10 to 160 mmol ZL, and more preferably 10 to 40 mmol ZL.
  • the pH of the electrophoresis solution is not particularly limited, but is, for example, 5.8 to 8, preferably 6.6 to 8, more preferably 7.4 to 8, for example, the buffer solution as described above. Can be adjusted as appropriate.
  • the concentration of calcium ions that preferably contains substantially no calcium ions is, for example, lOmmolZL or less. Preferably, it is below the measurement limit (for example, OmmolZL).
  • the combination of the calcium compound contained in the anodic electrophoretic solution and the phosphate compound contained in the cathodic electrophoretic solution is not particularly limited.
  • a combination of calcium chloride and sodium hydrogen phosphate, acetic acid A combination of calcium and ammonium dihydrogen phosphate is exemplified.
  • the ratio of the calcium ion concentration of the anodic electrophoretic solution to the phosphate ion concentration of the cathodic electrophoretic solution is, for example, in the range of 3: 5 to 5: 3, preferably 5: 5 to 5: The range of 3.
  • These electrophoretic solutions may contain other ions, for example, as long as the formation of hydroxyapatite is not impaired.
  • the type of the gel carrier in the present invention is not particularly limited.
  • the gel carrier is substantially insoluble in the above-described electrophoresis solution. Gels that can move acid ions are preferred.
  • An example of such a gel is Hyde Mouth Gel.
  • Hyde mouth gel generally means a gel in water (aqueous solvent).
  • the material of the hide-mouthed gel is not particularly limited as long as it is a substance that gels (swells). For example, it may be a substance that gels by heating and cooling a mixed solution with an aqueous solvent, or a hydrogen bond.
  • a substance that gels due to, for example, a substance that gels by an additive such as an aggregating agent, a crosslinking agent, or a polymerizing agent may be used.
  • the material of the gel carrier may contain an ionic group, but is preferably nonionic.
  • the gel carrier is preferably biocompatible.
  • examples of such materials include agarose, hyaluronic acid, alginic acid, pullulan, pectin, starch, mannan, chitin, chitosan, chitosan-chitin copolymer, dextran, dextran sulfate, and pregelatinized starch.
  • Examples include polysaccharides such as starch, cellulose, and cellulose derivatives (such as methoxycellulose, ethoxycellulose, propoxycellulose, and hydroxyethylcellulose). Also, fibronectin, fib mouth-in, sericin, atelocollagen, collagen, gelatinized collagen, gelatin, casein, polyspartate, polyglutamate, poly-gamma-glutamic acid, polylysine and other proteins, polypeptides or polyamino acids; lignin , Polyortune, poly (oral taxane), poly (ethylene succinate), poly (bull alcohol), poly (bullyl pyrrolidone), polyethylene glycol, poly (acrylamide), poly (hydroxyethyl) methacrylate, darcosilethyl methacrylate (GEMA), partial sulfate Examples thereof include organic polymer gels obtained by crosslinking polymers such as GEMA.
  • polysaccharides such as starch, cellulose, and cellulose derivatives (such as meth
  • hydrophilic rosin partially crosslinked with polybulualcohol, polyacrylamide, polybylpyrrolidone or the like can be used.
  • the cross-linked polybulal alcohol can be obtained, for example, by partially bridging polybulal alcohol with a bifunctional aldehyde such as dartalaldehyde.
  • These materials may be natural products, semi-synthetic products, or synthetic products. Among these, agarose, hyaluronic acid, collagen and the like are preferable because they are excellent in human safety and degradability. In addition, these materials can be either one type, or two or more types can be used in combination.
  • the method for preparing the gel carrier is not particularly limited, and can be prepared by a conventionally known method according to the type of the forming material.
  • agarose or gelatin it can be prepared by dissolving in a solvent by heating, and cooling and solidifying the obtained solution.
  • polybutyl alcohol, polyamino acid, and the like for example, they can be prepared by adding a crosslinking agent such as dartalaldehyde to these aqueous solutions and solidifying them.
  • a solution that conducts electricity can be used as the solvent.
  • aqueous solvents such as aqueous solutions of phosphoric acid and sodium phosphate, aqueous solutions of phosphoric acid such as sodium dihydrogen phosphate, and phosphate buffers, and Tris buffers such as Tris-HCl buffer.
  • An aqueous phosphoric acid solution such as an aqueous solution of disodium hydrogen and sodium dihydrogen phosphate is preferred.
  • concentration is 10-4 OmmolZL, for example, Preferably it is 10-20 mmolZL.
  • the p H is, for example, 5.8 to 8, preferably 6.6 to 8, and more preferably 6.6 to 7.4.
  • the pH of the gel carrier is not particularly limited, but is, for example, 5.8 to 8, preferably 6.6 to 8, and more preferably 6.6 to 7.4.
  • the pH of the gel carrier can be adjusted to a desired value by, for example, the above-mentioned solvent used when producing the gel carrier.
  • the content of the forming material in the gel carrier is not particularly limited, and is a force S that can be appropriately determined according to the type of the forming material, for example, 0.5 to: LO wt%, preferably 0. 5 to 5% by weight, more preferably 0.5 to 3% by weight.
  • the shape and size of the gel carrier are not limited in any way, and can be appropriately determined according to the shape and size of the electrophoresis apparatus to be used.
  • the length of the gel in the ion movement direction is, for example, 1 to 20 cm, preferably 3 to 10 cm, more preferably 3 to 6 cm, and the thickness is, for example, 0.1 to 1.5 cm, preferably 0.1 to 1.5 cm, 0.2 to 1.5 cm or younger or higher, 0.1 to Lcm, more preferably higher or lower to 0.2 to Lcm.
  • the width of the gel is not particularly limited, but is, for example, 30 cm or less, preferably 20 cm or less, and more preferably 15 cm or less.
  • the lower limit of the gel width is not particularly limited, and is, for example, 0.1 cm, 1 cm, 3 cm, 5 cm, 8 cm, 10 cm or more.
  • Specific examples of the open shape of the genore include a general slab gel and a rod gel.
  • a gel carrier is arranged at a predetermined position of the electrophoresis apparatus.
  • the electrophoresis apparatus for example, a conventionally known apparatus can be used, and an anodic electrophoretic solution containing calcium ions at one end of the gel carrier and a cathodic electrophoretic solution containing phosphate ions at the other end can be arranged.
  • the form is not limited at all.
  • an electrophoresis apparatus as shown in FIGS. 7A and 7B may be used.
  • Such an electrophoresis apparatus may be in the same form as a so-called submarine type electrophoresis apparatus generally used for electrophoresis of nucleic acids. That is, the electrophoresis apparatus of FIGS. 7A and 7B includes a main body 1 that constitutes a placement portion for placing the gel carrier 2 and two electrode tanks divided by the placement portion, and electrodes 3, 4 With.
  • the electrophoresis solution containing calcium ions is poured into the electrode tank in which the anode is arranged, and the electrophoresis solution containing phosphate ions is poured into the electrode tank in which the cathode is arranged.
  • the electrophoresis solution is injected into each electrode tank until one end of the gel carrier comes into contact with the anodic electrophoretic solution and the other end of the gel carrier comes into contact with the cathodic electrophoretic solution.
  • the anodic electrophoretic solution and the cathodic electrophoretic solution are preferably separated by a gel carrier. For example, as shown in FIG.
  • the anodic electrophoretic solution 5 and the cathodic electrophoretic solution 6 can be isolated by the gel carrier 2.
  • the gel carrier 2 may be sandwiched between the gel mounting part and the member 7 using the member 7 to isolate the electrophoresis solutions 5 and 6 from each other.
  • the shape of the member 7 is not particularly limited as long as the electrophoresis solution can be isolated.
  • the shape of the member 7 may be concave as shown in FIG. 7B.
  • the material of the member 7 is not particularly limited, and, for example, a conventionally known resin glass that can be the same as the main body 1 can be applied.
  • Hydroxyapatite is then formed inside (and on the surface of) the gel carrier by carrying out electrophoresis with an electric charge.
  • the reason why hydroxyapatite can be formed in the gel carrier by the method of the present invention is presumed to be that calcium ions and phosphate ions are forced to move the gel carrier by energization. For this reason, it is considered that the formation region of hydroxyapatite is not affected by the thickness of the gel carrier, for example.
  • the conditions for energization are not particularly limited, but the voltage is, for example, 2 to 500 V, and the current is, for example, 2 to 200 mA.
  • the migration time is not particularly limited, and is, for example, 1 to 60 minutes.
  • the migration time can be adjusted according to the size of the gel carrier, for example, when the length of the gel in the direction of ion movement is 6 cm, for example, about 10 to 30 minutes, and a uniform nose inside the gel carrier. Idroxyapatite can be formed. The nodoxy oxide formed in the gel can be confirmed, for example, with a scanning electron microscope (SEM) or the like as described later.
  • SEM scanning electron microscope
  • Hydroxyapatite formed inside (and on the surface of) the gel carrier is preferably a crystal particle, and its particle size is not particularly limited, but is preferably 0.2 to 2 / ⁇ ⁇ , for example. It is between 0.5 and 111, and preferably between 1.0 and 1. According to the production method of the present invention, it is possible to accelerate the formation rate of hydroxyapatite, for example, about 100 times as compared with the conventional alternate dipping method.
  • the density of hydroxyapatite in the composite can be adjusted by, for example, the force ion concentration and phosphate ion concentration in each electrophoresis solution, but practically, it is 0.1 wt% or more per equilibrium swelling volume (cm 3 ). More preferably, it is 1 to 25% by weight, particularly preferably 10 to 25% by weight.
  • FIG. 1 shows a solution containing CaCl as the anodic migration solution, the cathode side
  • (B) is a figure which shows the outline of the formation reaction of a hydroxyapatite. As shown in (a) of the figure, a solution containing CaCl on the anode side and a solution containing Na HPO as the cathode side running solution are used.
  • the present invention includes a gel carrier-hydroxyapatite composite produced by the production method of the present invention described above.
  • the obtained composite of the present invention has a good hemostatic effect and can be used as a medical material such as a material for forming an artificial bone or an artificial tooth root.
  • the composite is embedded around a damaged living bone or tooth. By planting, it exhibits hemostasis and can form artificial bones and artificial roots. This complex can be stored in physiological saline until use, after various sterilization treatments such as ⁇ -ray sterilization, for example.
  • the present invention provides a method of treatment using the gel carrier-hydroxyapatite of the present invention and a gel carrier-noid of the present invention in treatment of living bodies, for example, treatment including hemostasis or artificial osteoarthroplasty. It may also include the use of roxyapatite. Furthermore, the present invention provides a book comprising at least one of the above-described electrophoresis apparatus, anode side / cathode side electrophoresis solution, anode side / cathode side electrophoresis solution reagent, gel carrier, gel material powder, and instruction manual.
  • the gel carrier-hydroxyapatite production kit of the invention may be included.
  • a solution containing carbonate ions is used instead of a solution containing phosphate ions as the electrophoretic solution on the cathode side, by performing electrophoresis by energization, Since calcium carbonate is formed in the gel carrier, a complex of the gel carrier and calcium carbonate can also be produced.
  • a solution containing carbonate ions for example, a solution containing a carbonate compound (carbonate) such as sodium carbonate or sodium hydrogen carbonate is preferable. Or an aqueous solvent such as a buffer.
  • the carbonate ion concentration of the electrophoresis solution is not particularly limited, it is, for example, 10 to 200 mmol ZL, preferably 10 to 160 mmol ZL, and more preferably 10 to 40 mmol ZL.
  • the pH of the electrophoresis solution is, for example, 5.8 to 8, preferably 6.6 to 8, and more preferably 7 to 8.
  • a solution containing sulfate ions instead of a solution containing phosphate ions is used as the electrophoretic solution on the cathode side, and calcium ion is used as the electrophoretic solution on the anode side.
  • a solution containing cadmium ions is used in place of the solution containing, a cadmium sulfate is formed in the gel carrier by carrying out electrophoresis by energization. Therefore, a composite of the gel carrier and cadmium sulfate Can also be manufactured.
  • a solution containing sulfite ions for example, a solution containing cadmium acetate is preferable as a solution containing cadmium ions, which is preferable for a solution containing sodium sulfate.
  • the solvent of the solution for example, an aqueous solvent such as water or a buffer solution can be used as described above.
  • the sulfate ion concentration of the electrophoresis solution is not particularly limited, but is, for example, 10 to 200 mmol ZL, preferably 10 to 160 mmol ZL, and more preferably 10 to 40 mmol ZL.
  • the cadmium ion concentration of the electrophoresis solution is not particularly limited, but is, for example, 10 to 200 mmolZL, preferably 10 to 160 mmolZL, and more preferably 10 to 40 mmolZL.
  • the pH of the electrophoretic solution on each of the cathode side and the anode side is, for example, 5.8 to 8, preferably 6.6 to 8, and more preferably 7 to 8.
  • a 3 weight o / o agarose gel (length 6 cm x width 11 cm x thickness 0.8 mm) was prepared by a conventional method using lOmmolZL Tris-HQ buffer (pH 7.4).
  • the length of the agarose gel is the length in the ion movement direction (electrophoresis direction).
  • this agarose gel is placed at a predetermined position of a commercially available electrophoresis apparatus (trade name: Mupid minigel electrophoresis tank: manufactured by ADVANCE Co. Ltd), and an anode is inside.
  • 40 mmol / L CaCl aqueous solution was placed in the arranged electrode tank and 40 mmol ZL Tris-HC1 buffer.
  • the mixed solution adjusted to pH 7.4 with a solution was poured into an electrode tank having a cathode disposed therein, and 40 mmol ZL Na HPO aqueous solution was respectively injected. And about 30 minutes under the condition of voltage 100V
  • Electrophoresis was performed. 20 minutes after the start of electrophoresis, a cloudy band with a width of about 3 cm was observed near the center line of the agarose gel, and the band moved to the cathode side in the following 10 minutes.
  • (a) is the anode-side non-cloudy region (X 3000) of the agarose gel
  • (b) is the cathode-side cloudy region (X 1500) of the agarose gel
  • (c) is the cloudy region (X 15000).
  • X-ray diffraction was performed on the hydroxyapatite particles formed in the agarose gel using an X-ray diffraction apparatus (trade name: RINT in Plane ultra X18: manufactured by Rigaku Corporation).
  • the diffraction results are shown in FIG. In the figure, the horizontal axis indicates the angle and the vertical axis indicates the intensity.
  • diffraction peaks 25.8 ° (0 02) and 31.7 ° (211) peculiar to nodyl and idroxyapatite were observed. From this result, formation of hydroxyapatite inside the agarose gel was confirmed by electrophoresis.
  • the sizes of the two peaks 25.8 ° (002) and 31.7 ° (211) in XRD diffraction are relatively related to the crystallinity of nodyl and adroxyapatite.
  • the nodoxy hydroxyapatite obtained in this example can be said to have low crystallinity because these peaks are low. Since hydroxyapatite is easily decomposed if the crystallinity is low, the hydroxyapatite obtained in the present example is particularly useful for use in vivo where rapid decomposition is desired.
  • a solution containing calcium ions is used as the electrophoretic solution on the anode side, and a solution containing phosphate ions is used as the electrophoretic solution on the cathode side.
  • uniform hydroxyapatite can be formed inside the gel carrier, and the formation speed can be improved. For this reason, it becomes possible to more easily supply the composite in which the gel carrier holds the nodyl and the hydroxyapatite as a material for forming an artificial bone or an artificial tooth root.

Landscapes

  • Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé de production d'un complexe présentant une excellente formation d'hydroxyapatite et permettant de former une hydroxyapatite dans un substrat. Un support de gel est disposé entre une anode et une cathode. Une solution renfermant des ions classiques est utilisées comme solution de migration côté anode et une solution renfermant des ions phosphate comme solution de migration côté cathode. Une électrophorèse est effectuée au moyen de passage de courant, de manière à former une hydroxyapatite dans le support de gel, produisant ainsi un complexe de support de gel et d'hydroxyapatite.
PCT/JP2006/323343 2005-11-25 2006-11-22 Complexe de support de gel et d'hydroxyapatite et procédé de production de celui-ci Ceased WO2007061001A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007546472A JPWO2007061001A1 (ja) 2005-11-25 2006-11-22 ゲル担体とハイドロキシアパタイトとの複合体およびその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005340829 2005-11-25
JP2005-340829 2005-11-25

Publications (1)

Publication Number Publication Date
WO2007061001A1 true WO2007061001A1 (fr) 2007-05-31

Family

ID=38067226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/323343 Ceased WO2007061001A1 (fr) 2005-11-25 2006-11-22 Complexe de support de gel et d'hydroxyapatite et procédé de production de celui-ci

Country Status (2)

Country Link
JP (1) JPWO2007061001A1 (fr)
WO (1) WO2007061001A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018130343A (ja) * 2017-02-15 2018-08-23 国立大学法人東京工業大学 組成傾斜複合体及びその製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01305959A (ja) * 1988-06-03 1989-12-11 Arusu Japan:Kk 人工軟骨材
WO1999058447A1 (fr) * 1998-05-08 1999-11-18 Nof Corporation Hydroxyapatite, composite, procede de production et utilisation de ceux-ci
JP2004026653A (ja) * 2002-03-04 2004-01-29 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01305959A (ja) * 1988-06-03 1989-12-11 Arusu Japan:Kk 人工軟骨材
WO1999058447A1 (fr) * 1998-05-08 1999-11-18 Nof Corporation Hydroxyapatite, composite, procede de production et utilisation de ceux-ci
JP2004026653A (ja) * 2002-03-04 2004-01-29 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMIKOGEN M. ET AL: "Denki Eido ni Yoru Gelchu no Rinsan Calcium no Seisei", THE CERAMIC SOCIETY OF JAPAN NENKAI KOEN YOKOSHU, vol. 2006, March 2006 (2006-03-01), ABSTRACT, pages 306, XP003012684 *
WATANABE J. ET AL: "Hone Saisei o Yudo suru Hydroxyapatite kara naru Composite Gel no Sosei", ANNUAL MEETING OF THE JAPANESE SOCIETY FOR BIOMATERIALS YOKOSHU, vol. 27, 28 November 2005 (2005-11-28), ABSTRACT, pages 109, XP003012685 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018130343A (ja) * 2017-02-15 2018-08-23 国立大学法人東京工業大学 組成傾斜複合体及びその製造方法

Also Published As

Publication number Publication date
JPWO2007061001A1 (ja) 2009-05-07

Similar Documents

Publication Publication Date Title
Wang et al. Biological sealing and integration of a fibrinogen-modified titanium alloy with soft and hard tissues in a rat model
CN102188754B (zh) 纳米孔状羟基磷酸钙/水凝胶材料
CN1711113A (zh) 含有自体组织化磷灰石/胶原复合体的交联磷灰石/胶原多孔体及其制备方法
JP3770555B2 (ja) 複合生体材料
US6395037B1 (en) Hydroxyapatite, composite, processes for producing these, and use of these
JP2009132601A (ja) アパタイト／コラーゲン複合体繊維を含む多孔体及びその製造方法
WO2013005778A1 (fr) Complexe poreux présentant un gradient de bioabsorbabilité, os artificiel l'utilisant et procédé de fabrication de ceux-ci
JPWO1999058447A1 (ja) ハイドロキシアパタイト、複合体、これらの製造方法及び用途
CN1268307C (zh) 再生性骨植入物
JPH11199209A (ja) 有機無機配向性複合材料の製造方法
JP2000327314A (ja) ハイドロキシアパタイト複合体の製造方法、その複合体及び生体適合性材料
US20150132353A1 (en) BIOMATERIAL COATED WITH HAp/Col COMPOSITE
JP2003154001A (ja) セリシン含有複合体およびその製造方法
WO2003020316A1 (fr) Matieres a liberation lente de medicament in vivo
WO2007061001A1 (fr) Complexe de support de gel et d'hydroxyapatite et procédé de production de celui-ci
WO2014032800A1 (fr) Membrane biorésorbable
CN114028620A (zh) 一种矿化人工骨膜及其制备方法和应用
EP2703015A1 (fr) Membrane biorésorbable
CN114028619B (zh) 一种双层人工骨膜及其制备方法和应用
CN1337271A (zh) 含有纳米相钙磷盐、胶原和海藻酸盐的骨材料的制备方法
JP4472805B2 (ja) 炭酸カルシウム複合体および生体適合性材料
JP3379088B2 (ja) 生体材料用複合体およびその製造方法
Douglas Biomimetic mineralization of hydrogels
JP2009209313A (ja) ゲル担体とハイドロキシアパタイトとの複合体の製造方法
CN120037449B (zh) 一种口腔骨修复水凝胶骨膜材料及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007546472

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06833165

Country of ref document: EP

Kind code of ref document: A1